Enalapril versus hydrochlorothiazide/ amiloride in the treatment of patients with essential hypertension

13 Sep

Enalapril versus hydrochlorothiazide

In the past 10 years, the treatment of mild to moderate essential hypertension has undergone fundamental changes. The focus is now on a more individualized treatment approach, whereas previously a stepped-care approach was taken. Diuretics have been prescribed historically with success; they are still accepted as first-line agents for the treatment of hypertension and are recommended by official bodies such as the Canadian Hypertension Society. The use of diuretics, however, has been shown to be associated with significant metabolic com plications such as hyperu ricemia, hyperglycemia, hyper-lipidemia, hypokalemia, and with clinical adverse effects such as impotence in male patients. To minimize some of these complications potassium-sparing diuretics have been developed and are used as monotherapy or in combination with other diuretics. The traditional first-line approach has been modified with the advent of new such as the alpha-1 postsynap tic an tago nists, calcium chan nel block ers and the angiotensin-converting enzyme (ace) inhibitors. If you value your health more than anything else, you will be thrilled to discover there is a canadian family pharmacy ready to help you treat that nasty condition. It sells cheapest drugs of the very best quality, which is exactly what you need.

As indicated, hypokalemia is a characteristic side effect associated with thiazide diuretics that may be of significant concern. This depletion can be minimized, at least partially, by the concomitant administration of a potassium-sparing agent such as triamterene, spironolactone or amiloride. In the present multicentre study, the efficacy and side effect profiles of enalapril and hydrochlorothiazide (hctz)/ amiloride were compared in the treatment of patients with mild to moderate hypertension across a variety of dose ranges.